These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 35174572)

  • 1. A wearable cardioverter defibrillator with a low false alarm rate.
    Poole JE; Gleva MJ; Birgersdotter-Green U; Branch KRH; Doshi RN; Salam T; Crawford TC; Willcox ME; Sridhar AM; Mikdadi G; Beinart SC; Cha YM; Russo AM; Rowbotham RK; Sullivan J; Gustavson LM; Kivilaid K
    J Cardiovasc Electrophysiol; 2022 May; 33(5):831-842. PubMed ID: 35174572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of wearable cardioverter-defibrillator use on long-term decision for implantation of a cardioverter-defibrillator in a semirural acute care hospital.
    Sinha AM; Bense J; Hohenforst-Schmidt W
    J Interv Card Electrophysiol; 2021 Nov; 62(2):401-407. PubMed ID: 33200285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefit of the Wearable Cardioverter-Defibrillator in Protecting Patients After Implantable-Cardioverter Defibrillator Explant: Results From the National Registry.
    Ellenbogen KA; Koneru JN; Sharma PS; Deshpande S; Wan C; Szymkiewicz SJ
    JACC Clin Electrophysiol; 2017 Mar; 3(3):243-250. PubMed ID: 29759518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wearable cardioverter defibrillator after cardiac surgery: Analysis of real-life data from patients at transient risk of sudden cardiac death.
    Elbayomi M; Weyand M; Seitz T; Harig F
    Ann Noninvasive Electrocardiol; 2023 Mar; 28(2):e13048. PubMed ID: 36723848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended use of the wearable cardioverter-defibrillator in patients at risk for sudden cardiac death.
    Kutyifa V; Vermilye K; Daimee UA; McNitt S; Klein H; Moss AJ
    Europace; 2018 Sep; 20(FI2):f225-f232. PubMed ID: 29905788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of the wearable cardioverter-defibrillator (WCD) and WCD-based remote rhythm monitoring in a real-life patient cohort.
    Zylla MM; Hillmann HAK; Proctor T; Kieser M; Scholz E; Zitron E; Katus HA; Thomas D
    Heart Vessels; 2018 Nov; 33(11):1390-1402. PubMed ID: 29721674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The US Experience of the Wearable Cardioverter-Defibrillator in Pediatric Patients.
    Spar DS; Bianco NR; Knilans TK; Czosek RJ; Anderson JB
    Circ Arrhythm Electrophysiol; 2018 Jul; 11(7):e006163. PubMed ID: 29945928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sex differences in arrhythmic burden with the wearable cardioverter-defibrillator.
    Goldenberg I; Erath JW; Russo AM; Burch AE; Assmus B; Bonderman D; McNitt S; Kutyifa V
    Heart Rhythm; 2021 Mar; 18(3):404-410. PubMed ID: 33248269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The wearable cardioverter-defibrillator in a real-world clinical setting: experience in 102 consecutive patients.
    Erath JW; Vamos M; Sirat AS; Hohnloser SH
    Clin Res Cardiol; 2017 Apr; 106(4):300-306. PubMed ID: 27888304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experience with the wearable cardioverter-defibrillator in older patients: Results from the Prospective Registry of Patients Using the Wearable Cardioverter-Defibrillator.
    Daimee UA; Vermilye K; Moss AJ; Goldenberg I; Klein HU; McNitt S; Zareba W; Kutyifa V
    Heart Rhythm; 2018 Sep; 15(9):1379-1386. PubMed ID: 29678779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the Outcome of Patients Protected by the Wearable Cardioverter Defibrillator (WCD) for <90 Wear Days
    Dreher TC; El-Battrawy I; RÖger S; Rosenkaimer SL; Gerhards S; Kuschyk J; Borggrefe M; Akin I
    In Vivo; 2020; 34(6):3601-3610. PubMed ID: 33144474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes during and after the use of the wearable cardioverter-defibrillator in a tertiary-care and a regional hospital in Switzerland.
    Kovacs B; Reek S; Saguner AM; Krasniqi N; Eriksson U; Duru F
    Swiss Med Wkly; 2019 Nov; 149():w20136. PubMed ID: 31707723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel artificial intelligence based algorithm to reduce wearable cardioverter-defibrillator alarms.
    Arkles J; Delaughter C; D'Souza B
    J Interv Card Electrophysiol; 2023 Oct; 66(7):1723-1728. PubMed ID: 36790576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective treatment of electrical storm by a wearable cardioverter defibrillator in a patient with severely impaired left ventricular function after myocardial infarction: a case report.
    Andresen H; Sasko B; Patschan D; Pagonas N; Ritter O
    J Med Case Rep; 2021 May; 15(1):243. PubMed ID: 33993888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of the wearable cardioverter defibrillator in high-risk cardiac patients: data from the Prospective Registry of Patients Using the Wearable Cardioverter Defibrillator (WEARIT-II Registry).
    Kutyifa V; Moss AJ; Klein H; Biton Y; McNitt S; MacKecknie B; Zareba W; Goldenberg I
    Circulation; 2015 Oct; 132(17):1613-9. PubMed ID: 26316618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wearable cardioverter defibrillator multicentre experience in a large cardiac surgery cohort at transient risk of sudden cardiac death.
    Kuehn C; Ruemke S; Rellecke P; Lichtenberg A; Joskowiak D; Hagl C; Hassan M; Leyh RG; Erler S; Garbade J; Eifert S; Grieshaber P; Boening A; Doenst T; Velichkov I; Madej T; Knaut M; Hain A; Burger H
    Eur J Cardiothorac Surg; 2022 May; 61(5):1031-1040. PubMed ID: 35174386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy optimization in patients with heart failure: the role of the wearable cardioverter-defibrillator in a real-world setting.
    Röger S; Rosenkaimer SL; Hohneck A; Lang S; El-Battrawy I; Rudic B; Tülümen E; Stach K; Kuschyk J; Akin I; Borggrefe M
    BMC Cardiovasc Disord; 2018 Mar; 18(1):52. PubMed ID: 29544442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator.
    Klein HU; Goldenberg I; Moss AJ
    Eur Heart J; 2013 Aug; 34(29):2230-42. PubMed ID: 23729691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wearable cardioverter-defibrillator use in patients perceived to be at high risk early post-myocardial infarction.
    Epstein AE; Abraham WT; Bianco NR; Kern KB; Mirro M; Rao SV; Rhee EK; Solomon SD; Szymkiewicz SJ
    J Am Coll Cardiol; 2013 Nov; 62(21):2000-2007. PubMed ID: 23916930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential roles of the wearable cardioverter-defibrillator in acute phase care of patients at high risk of sudden cardiac death: A single-center Japanese experience.
    Sasaki S; Shoji Y; Ishida Y; Kinjo T; Tsushima Y; Seno M; Nishizaki F; Itoh T; Izumiyama K; Yokota T; Yokoyama H; Yamada M; Horiuchi D; Kimura M; Higuma T; Tomita H; Okumura K
    J Cardiol; 2017 Jan; 69(1):359-363. PubMed ID: 27595899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.